Novabay Pharmaceuticals Incの時価総額
Novabay Pharmaceuticals Incの時価総額は何ですか。
Novabay Pharmaceuticals Incの時価総額は3.25M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
NYSEMKTのセクタHealth Careにおける時価総額の企業と比べるNovabay Pharmaceuticals Inc
Novabay Pharmaceuticals Incは何をしますか。
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Incと類似の時価総額
- Solis Minerals Ltdの時価総額は3.23M$です。
- Nugen Medical Devices Incの時価総額は3.23M$です。
- Super Crop Safeの時価総額は3.23M$です。
- R&R Real Estate Investment Trustの時価総額は3.23M$です。
- Champion Bear Resourcesの時価総額は3.24M$です。
- Myanmar Investments Internationalの時価総額は3.24M$です。
- Novabay Pharmaceuticals Incの時価総額は3.25M$です。
- BlueRushの時価総額は3.25M$です。
- Lions Bay Capitalの時価総額は3.25M$です。
- BikeExchange Pty Ltdの時価総額は3.25M$です。
- Schmitt Industries Incの時価総額は3.25M$です。
- Getty Copperの時価総額は3.25M$です。
- Acura Pharmaceuticalsの時価総額は3.25M$です。